ParkinsonFranceV1, Main, Merge, indexHead, Idat.i

Index : Idat.i

Les termes de plus forte occurence

6	0006-8950:1999:Damier P:the:substantia:nigra
4	0964-6906:2003:Levecque C:association:between:parkinson
4	0959-4965:1994:Boireau A:riluzole:and:experimental
4	0379-864X:2003:Hudry J:evidence:for:deficiencies
3	1631-0691:2005:Benabid A:therapeutic:electrical:stimulation
3	1388-2457:2001:Pezard L:investigation:of:non
3	0987-7053:2001:Thobois S:contributions:of:pet
3	0964-6906:2003:Corti O:the:p:subunit
3	0964-6906:1999:Abbas N:a:wide:variety
3	0959-4965:1997:Dominey P:contribution:of:frontostriatal
3	0936-3076:1995:Marie R:pet:imaging:of
3	0885-3185:2011:Dehay B:new:animal:models
3	0885-3185:2011:Bezard E:a:tale:on
3	0885-3185:2008:Maltete D:microsubthalamotomy:an:immediate
3	0885-3185:2005:Witjas T:addiction:in:parkinson
3	0885-3185:2005:Beuter A:characterization:of:subclinical
3	0885-3185:2002:Sarazin M:procedural:learning:and
3	0885-3185:2002:Pollak P:treatment:results:parkinson
3	0885-3185:2002:Pillon B:neuropsychological:assessment:for
3	0885-3185:2002:Krack P:postoperative:management:of
3	0885-3185:2001:Turmel H:caspase:activation:in
3	0885-3185:2001:Muriel M:plasticity:of:afferent
3	0885-3185:2001:Montastruc J:long:term:mortality
3	0885-3185:2001:Krack P:mirthful:laughter:induced
3	0885-3185:2001:Hassani O:riluzole:reduces:hyperactivity
3	0885-3185:2000:Tonolli I:lateral:leg:raising
3	0885-3185:1999:Montastruc J:treatment:of:parkinson
3	0885-3185:1999:Montastruc J:a:randomized:double
3	0885-3185:1999:Dentresangle C:striatal:d:dopamine
3	0885-3185:1998:Benabid A:long:term:electrical
3	0767-3981:1994:Montastruc J:drug:induced:parkinsonism
3	0767-3981:1993:Nicolle E:pharmacokinetics:of:apomorphine
3	0767-3981:1993:Masson G:dopaminergic:modulation:of
3	0735-1097:1999:Chevalier P:gated:blood:pool
3	0364-5134:2000:Bejjani B:levodopa:induced:dyskinesias
3	0364-5134:1999:Muriel M:levodopa:induces:a
3	0340-5354:1997:Dubois B:cognitive:deficits:in
3	0340-5354:1996:Tison F:pain:in:multiple
3	0340-5354:1992:Rondot P:activity:and:acceptability
3	0317-1671:2008:Beuter A:postural:sway:and
3	0306-4522:2000:Yelnik J:functional:mapping:of
3	0306-4522:2000:Murer M:the:indirect:basal
3	0306-4522:1999:Hassani O:effects:of:intrasubthalamic
3	0306-4522:1996:Vila M:metabolic:activity:of
3	0306-4522:1996:Mouatt Prigent A:increased:m:calpain
3	0306-4522:1996:Hunot S:nitric:oxide:synthase
3	0306-4522:1996:Barneoud P:neuroprotective:effects:of
3	0306-4522:1995:Barneoud P:effects:of:complete
3	0306-4522:1993:Herrero M:does:neuromelanin:contribute
3	0306-4522:1993:Hantraye P:stable:parkinsonian:syndrome
3	0306-4522:1990:Ruberg M:choline:acetyltransferase:activity
3	0306-4522:1990:Javoy Agid F:decreased:tyrosine:hydroxylase
3	0304-3940:2000:Boraud T:effects:of:riluzole
3	0304-3940:1999:Marie R:relationships:between:striatal
3	0304-3940:1999:Harhangi B:the:ile:met
3	0304-3940:1995:Levy R:striatal:expression:of
3	0300-0729:2011:Hidalgo J:just:noticeable:difference
3	0278-5846:1999:Bezard E:effect:of:the
3	0195-668X:1997:Levy S:using:the:right
3	0169-328X:1999:Fillebeen C:lactoferrin:is:synthesized
3	0167-9899:1987:Le Guludec D:phase:mapping:of
3	0167-5273:2001:Brembilla Perrot B:influence:of:age
3	0166-4328:1991:Ferrandez A:a:comparison:between
3	0166-2236:2000:Hirsch E:metabolic:effects:of
3	0143-5221:2006:Wolf J:side:effects:of
3	0140-6736:1991:Agid Y:parkinson:s:disease
3	0093-934X:2003:Gentil M:effect:of:bilateral
3	0038-0814:1993:Guillard A:maladie:de:parkinson
3	0035-3787:2012:De Deurwaerdere P:what:can:we
3	0034-5687:1999:Vercueil L:breathing:pattern:in
3	0033-3158:2007:De Leonibus E:spatial:deficits:in
3	0028-3932:2008:Boulenger V:word:processing:in
3	0028-3932:2001:Ventre Dominey J:asymmetric:influences:of
3	0028-3932:1997:Pillon B:memory:for:spatial
3	0028-3932:1997:Dominey P:analogical:transfer:is
3	0028-3932:1995:Dominey P:motor:imagery:of
3	0028-3932:1994:Pasquier F:motor:memory:and
3	0027-5107:2001:Herceg Z:functions:of:poly
3	0022-510X:1995:Plante Bordeneuve V:a:clinical:and
3	0022-510X:1994:Blin O:mitochondrial:respiratory:failure
3	0022-510X:1993:Rumbach L:event:related:potentials
3	0022-510X:1991:Blin O:dopa:sensitive:and
3	0022-510X:1990:Blin O:quantitative:analysis:of
3	0022-510X:1988:Pierot L:d:and:d
3	0022-510X:1988:Epelbaum J:somatostatin:concentrations:and
3	0022-3573:1999:Ben V:time:dependent:striatal
3	0022-3085:2009:Bardinet E:a:three:dimensional
3	0022-3085:2007:Guehl D:statistical:determination:of
3	0022-3085:2003:Yelnik J:localization:of:stimulating
3	0022-3069:2006:Deramecourt V:biochemical:staging:of
3	0022-3069:2005:Sgambato Faure V:coordinated:and:spatial
3	0022-3050:2004:Levecque C:association:of:polymorphisms
3	0022-3050:2004:Dujardin K:subthalamic:nucleus:stimulation
3	0022-3050:1997:De Rijk M:prevalence:of:parkinsonism
3	0022-3050:1995:Caparros Lefebvre D:which:factors:predict
3	0022-3050:1994:Rascol O:normal:activation:of
3	0022-3050:1994:Montastruc J:a:randomised:controlled
3	0022-3050:1993:Deffond D:apomorphine:in:treatment
3	0022-3050:1991:Agniel A:cognition:and:cerebral
3	0022-3050:1989:Pillon B:does:cognitive:impairment
3	0022-3050:1987:Viallet F:performance:of:a
3	0014-4819:1996:Duffau H:tremor:and:voluntary
3	0014-2999:1998:Bezard E:riluzole:delayed:appearance
3	0007-0769:1987:Touboul P:electrophysiological:action:of
3	0006-8993:1998:Boraud T:effects:of:l
3	0006-8993:1997:Faucheux B:the:density:of
3	0006-8993:1995:Faucheux B:autoradiographic:localization:and
3	0006-8993:1994:Mouatt Prigent A:does:the:calcium
3	0006-8993:1994:Lehericy S:monoamine:vesicular:uptake
3	0006-8993:1993:Villares J:autoradiographic:study:of
3	0006-8993:1993:Kastner A:tyrosine:hydroxylase:protein
3	0006-8993:1993:Herrero M:differential:vulnerability:to
3	0006-8993:1992:Parker F:evidence:for:a
3	0006-8993:1990:Raisman Vozari R:lack:of:change
3	0006-8950:2002:Moro E:response:to:levodopa
3	0006-8950:2000:Meunier S:abnormal:reciprocal:inhibition
3	0006-8950:2000:Kubis N:preservation:of:midbrain
3	0006-8950:1999:Krack P:from:off:period
3	0006-8950:1996:Defer G:long:term:outcome
3	0006-8950:1994:Peschanski M:bilateral:motor:improvement
3	0006-8950:1992:Ventre J:abnormalities:of:predictive
3	0006-8950:1989:Rascol O:abnormal:ocular:movements
3	0004-637X:2010:A Abdo A:fermi:large:area
3	0003-9942:2007:Lesage S:lrrk:exon:mutations
3	0003-4975:2001:Chauvaud S:cardiac:arrhythmia:in
3	0002-9297:2001:Periquet M:origin:of:the
3	0002-9297:1998:Tassin J:chromosome:linked:autosomal
3	0002-9262:2003:Baldi I:neurodegenerative:diseases:and
3	0002-9149:1989:Sebag C:rupture:of:the
3	0002-8703:1992:Mabo P:asymptomatic:pseudoaneurysm:of
3	0002-8703:1992:Brembilla Perrot B:ventricular:fibrillation:induced
3	0001-6918:1998:Vinter A:spatial:features:of
3	0001-6322:1987:Delisle M:motor:neuron:disease
3	0001-6314:1996:Auzou P:clozapine:for:the
3	0001-6314:1994:Tison F:prevalence:of:parkinson
2	8756-3282:2012:Dennison E:effect:of:co
2	1948-7193:2013:Navailles S:multisite:intracerebral:microdialysis
2	1875-2136:2008:Brembilla Perrot B:wolff:parkinson:white
2	1875-2136:2008:Brembilla Perrot B:when:and:how
2	1755-5930:2012:Aznavour N:mptp:animal:model
2	1662-4548:2015:Verdier J:lessons:from:the
2	1631-0691:2007:Elbaz A:interaction:between:genes
2	1631-0691:2005:Corti O:parkinson:s:disease
2	1613-6810:2005:Schuffenhauer C:synthesis:of:fullerene
2	1567-2050:2008:Vincent B:regulation:of:betaapp
2	1566-0702:2004:Bouhaddi M:impaired:cardiovascular:autonomic
2	1554-8627:2016:Bourdenx M:nanoparticles:restore:lysosomal
2	1554-8627:2012:Fouillet A:er:stress:inhibits
2	1552-4841:2010:Evangelou E:non:replication:of
2	1535-3893:2008:Stauber J:maldi:imaging:of
2	1525-7797:2008:Woerly S:development:of:a
2	1474-4422:2015:Dehay B:targeting:synuclein:for
2	1471-003X:2010:Redgrave P:goal:directed:and
2	1466-0822:2005:Salauze L:circulating:antibodies:to
2	1388-2457:2008:Sauleau P:subthalamic:stimulation:improves
2	1388-2457:2008:Fraix V:effects:of:subthalamic
2	1388-2457:2007:Eusebio A:assessment:of:cortico
2	1388-2457:2006:Devos D:predominance:of:the
2	1388-2457:2005:Lefaucheur J:motor:cortex:dysfunction
2	1388-2457:2004:Lefaucheur J:improvement:of:motor
2	1388-2457:2003:Labyt E:motor:preparation:is
2	1388-2457:2002:Devos D:influence:of:internal
2	1383-875X:1998:De Chillou C:reproducibility:of:bipolar
2	1381-6128:2005:Guilloteau D:pet:and:spect
2	1380-3395:2003:Bouquet C:investigation:of:supervisory
2	1368-5031:2008:Poewe W:diagnosis:and:management
2	1364-6745:2008:Szatanik M:behavioral:effects:of
2	1359-4184:2014:Drui G:loss:of:dopaminergic
2	1351-5101:2006:Horstink M:review:of:the
2	1351-5101:2000:Blanchet S:cognitive:processes:involved
2	1350-7540:2005:Benabid A:deep:brain:stimulation
2	1294-8322:2012:Perbal Hatif S:a:neuropsychological:approach
2	1180-4882:1998:Le Houezec J:nicotine:abused:substance
2	1170-229X:2001:Senard J:orthostatic:hypotension:in
2	1093-9946:2005:Hoffner G:transglutaminase:and:diseases
2	1076-5174:2005:Libert F:development:of:a
2	1065-9471:2004:Lozza C:executive:processes:in
2	1064-1963:1994:Galinier M:relationship:between:arterial
2	1060-0280:2006:Hudry J:cost:utility:model
2	1060-0280:1999:Champagne S:chronic:constrictive:pericarditis
2	1055-8330:1996:Anglade P:synaptic:plasticity:in
2	1045-3873:2000:Jais P:left:ventricular:diastolic
2	1045-3873:1999:Basiouny T:accuracy:and:limitations
2	1015-6305:1999:Buee L:comparative:biochemistry:of
2	1011-6125:2016:Hamani C:pedunculopontine:nucleus:region
2	1011-6125:2005:Nowinski W:a:probabilistic:functional
2	1010-7940:1989:Menasche P:surgery:for:the
2	0987-7053:2014:Caudron S:evaluation:of:a
2	0987-7053:2008:Benatru I:postural:disorders:in
2	0987-7053:2007:Shin M:subthalamic:nucleus:stimulation
2	0987-7053:2003:Devos D:effect:of:l
2	0987-7053:2001:Autret A:sleep:and:brain
2	0987-7053:1999:Guerit J:revue:de:la
2	0987-7053:1999:Defebvre L:desynchronisation:liee:a
2	0969-8051:1998:Hantraye P:modeling:dopamine:system
2	0969-8051:1998:Emond P:toxicity:mutagenicity:and
2	0969-7128:2007:Do Thi N:does:neuronal:expression
2	0969-7128:2004:Do Thi N:delivery:of:gdnf
2	0964-6906:2012:Keller M:using:genome:wide
2	0964-6906:2012:Bras J:mutation:of:the
2	0964-6906:2010:Lesage S:parkinson:s:disease
2	0964-6906:2010:Gegg M:mitofusin:and:mitofusin
2	0964-6906:2010:Braunstein K:a:point:mutation
2	0964-6906:2009:Lesage S:parkinson:s:disease
2	0964-6906:2009:Azeredo Da Silveira S:phosphorylation:does:not
2	0964-6906:2008:Chapuis J:association:study:of
2	0964-6906:2006:Hampe C:biochemical:analysis:of
2	0964-6906:1998:Vaughan J:sequencing:of:the
2	0960-3271:2000:Missy P:in:vitro:and
2	0959-9851:1992:Senard J:ambulatory:blood:pressure
2	0959-9851:1992:Durrieu G:parkinson:s:disease
2	0959-4965:2004:Paille V:role:of:nigral
2	0959-4965:2000:Thobois S:overactivation:of:primary
2	0959-4965:1999:Parain K:reduced:expression:of
2	0959-4965:1997:Bezard E:presymptomatic:revelation:of
2	0959-4965:1994:Horellou P:direct:intracerebral:gene
2	0953-816X:2004:Robelet S:chronic:l:dopa
2	0953-816X:2003:Devos D:subthalamic:stimulation:influences
2	0953-816X:2003:Darbaky Y:high:frequency:stimulation
2	0953-816X:2001:Breit S:unilateral:lesion:of
2	0953-816X:2000:Jan C:dopaminergic:innervation:of
2	0953-816X:2000:Bezard E:adaptive:changes:in
2	0953-816X:1995:Levy R:effects:of:nigrostriatal
2	0953-816X:1995:Amalric M:complex:deficits:on
2	0953-4180:1995:Mahieux F:mini:mental:parkinson
2	0953-1424:1997:Durlach J:are:age:related
2	0952-3480:2013:Chassain C:does:mptp:intoxication
2	0939-6411:2006:Clavreul A:effect:of:gdnf
2	0936-3076:1989:Zreika M:mdl:a:potent
2	0933-3657:1998:Toffano Nioche C:a:functional:model
2	0930-1038:2005:Haegelen C:does:subthalamic:nucleus
2	0930-1038:1988:Nguyen Legros J:functional:neuroarchitecture:of
2	0929-8673:2000:Goldstein S:chemical:and:pharmacological
2	0929-693X:1998:Villain E:recommandations:pour:le
2	0923-2532:1999:Biola A:implications:de:l
2	0920-3206:1998:Fauchier L:effect:of:flecainide
2	0920-1211:1998:Vercueil L:high:frequency:stimulation
2	0894-7317:2000:Eder V:localization:of:the
2	0894-4105:2010:Peron J:subthalamic:nucleus:stimulation
2	0894-4105:2000:Fournet N:working:memory:functioning
2	0894-1491:2004:Barcia C:evidence:of:active
2	0893-133X:2009:De Leonibus E:metabotropic:glutamate:receptors
2	0893-133X:2004:Coccurello R:simultaneous:blockade:of
2	0891-9887:2009:Montel S:quality:of:life
2	0891-9887:2008:Lafont S:driving:cessation:and
2	0885-6230:2011:Mulin E:diagnostic:criteria:for
2	0885-6230:2010:Braam A:depression:and:parkinsonism
2	0885-6230:2002:Robert P:the:apathy:inventory
2	0885-3185:2012:Peron J:emotional:processing:in
2	0885-3185:2012:Oudiette D:a:motor:signature
2	0885-3185:2012:Lees A:perampanel:an:ampa
2	0885-3185:2012:Fox S:a:critique:of
2	0885-3185:2012:Dubois B:donepezil:in:parkinson
2	0885-3185:2012:De Cock V:suggested:immobilization:test
2	0885-3185:2012:Barton B:clinical:validation:of
2	0885-3185:2012:Ballanger B:role:of:serotonergic
2	0885-3185:2012:Arnulf I:rem:sleep:behavior
2	0885-3185:2012:Ahmed I:association:between:parkinson
2	0885-3185:2011:Sampaio C:pardoprunox:in:early
2	0885-3185:2011:Rascol O:milestones:in:parkinson
2	0885-3185:2011:Moreau C:modulation:of:dysarthropneumophonia
2	0885-3185:2011:Mollion H:subthalamic:nucleus:stimulation
2	0885-3185:2011:Moisan F:the:relation:between
2	0885-3185:2011:Leentjens A:symptomatology:and:markers
2	0885-3185:2011:Leentjens A:anxiety:rating:scales
2	0885-3185:2011:Kupsch A:early:postoperative:management
2	0885-3185:2011:Fox S:the:movement:disorder
2	0885-3185:2011:Dellapina E:apomorphine:effect:on
2	0885-3185:2011:De Chazeron I:hypersexuality:and:pathological
2	0885-3185:2011:Antonini A:wearing:off:scales
2	0885-3185:2010:Vitek J:standard:guidelines:for
2	0885-3185:2010:Schapira A:rationale:for:delayed
2	0885-3185:2010:Rouaud T:pallidal:stimulation:in
2	0885-3185:2010:Rascol O:orodispersible:sublingual:piribedil
2	0885-3185:2010:Rascol O:efficacy:safety:and
2	0885-3185:2010:Moro E:long:term:results
2	0885-3185:2010:Kollensperger M:presentation:diagnosis:and
2	0885-3185:2010:Hogl B:scales:to:assess
2	0885-3185:2010:Hauser R:randomized:double:blind
2	0885-3185:2010:Friedman J:fatigue:rating:scales
2	0885-3185:2010:Ferreira J:skin:cancer:and
2	0885-3185:2010:Fenelon G:the:changing:face
2	0885-3185:2010:Eggert K:safety:and:efficacy
2	0885-3185:2010:Dujardin K:parkinson:s:disease
2	0885-3185:2010:Delval A:objective:detection:of
2	0885-3185:2010:Colosimo C:task:force:report
2	0885-3185:2010:Bronzova J:double:blind:study
2	0885-3185:2009:Volkmann J:long:term:effects
2	0885-3185:2009:Tir M:motor:related:circuit
2	0885-3185:2009:Sauleau P:comparison:of:weight
2	0885-3185:2009:Robert G:cognitive:impulsivity:in
2	0885-3185:2009:Nowak D:arbitrary:visuomotor:mapping
2	0885-3185:2009:Maltete D:microsubthalamotomy:effect:at
2	0885-3185:2009:Limousin N:restless:legs:syndrome
2	0885-3185:2009:Lavault S:periodic:leg:movements
2	0885-3185:2009:Kraoua I:parkinsonism:in:gaucher
2	0885-3185:2009:Grosset D:adherence:to:antiparkinson
2	0885-3185:2009:Giladi N:validation:of:the
2	0885-3185:2009:Evatt M:dysautonomia:rating:scales
2	0885-3185:2009:Dujardin K:apathy:may:herald
2	0885-3185:2009:Devos D:patient:profile:indications
2	0885-3185:2009:Chastan N:gait:and:balance
2	0885-3185:2008:Olanow C:a:randomized:double
2	0885-3185:2008:Montel S:what:relation:is
2	0885-3185:2008:Lohmann E:are:parkin:patients
2	0885-3185:2008:Leentjens A:apathy:and:anhedonia
2	0885-3185:2008:Leentjens A:anxiety:rating:scales
2	0885-3185:2008:Hammond C:latest:view:on
2	0885-3185:2008:Goetz C:placebo:influences:on
2	0885-3185:2008:Goetz C:movement:disorder:society
2	0885-3185:2008:Ferraye M:deep:brain:stimulation
2	0885-3185:2008:Fernandez H:scales:to:assess
2	0885-3185:2008:Dujardin K:the:lille:apathy
2	0885-3185:2008:Devos D:comparison:of:desipramine
2	0885-3185:2008:Czernecki V:apathy:following:subthalamic
2	0885-3185:2008:Camuzat A:the:psp:associated
2	0885-3185:2007:Witjas T:effects:of:chronic
2	0885-3185:2007:Schupbach M:mortality:in:patients
2	0885-3185:2007:Schrag A:depression:rating:scales
2	0885-3185:2007:Sauleau P:contraversive:eye:deviation
2	0885-3185:2007:Rocca W:increased:risk:of
2	0885-3185:2007:Paille V:rat:model:of
2	0885-3185:2007:Ory Magne F:does:ageing:influence
2	0885-3185:2007:Moreau C:oral:festination:in
2	0885-3185:2007:Leu Semenescu S:myoclonus:or:tremor
2	0885-3185:2007:Holmberg B:safety:and:tolerability
2	0885-3185:2007:Hauser R:ten:year:follow
2	0885-3185:2007:Goetz C:sarizotan:as:a
2	0885-3185:2007:Goetz C:movement:disorder:society
2	0885-3185:2007:Ghorayeb I:a:nationwide:survey
2	0885-3185:2007:Ferreira J:skin:cancers:and
2	0885-3185:2007:Emre M:clinical:diagnostic:criteria
2	0885-3185:2007:Dujardin K:characteristics:of:apathy
2	0885-3185:2007:Clark L:construction:and:validation
2	0885-3185:2007:Broussolle E:contribution:of:jules
2	0885-3185:2007:Anheim M:lifetime:of:itrel
2	0885-3185:2006:Witt K:subthalamic:nucleus:influences
2	0885-3185:2006:Voon V:deep:brain:stimulation
2	0885-3185:2006:Roze E:head:tremor:in
2	0885-3185:2006:Rezai A:deep:brain:stimulation
2	0885-3185:2006:Rascol O:early:piribedil:monotherapy
2	0885-3185:2006:Rascol O:development:of:dyskinesias
2	0885-3185:2006:Oertel W:pergolide:versus:levodopa
2	0885-3185:2006:Machado A:deep:brain:stimulation
2	0885-3185:2006:Lang A:deep:brain:stimulation
2	0885-3185:2006:Gross R:electrophysiological:mapping:for
2	0885-3185:2006:Funkiewiez A:effects:of:levodopa
2	0885-3185:2006:Frigerio R:chemical:exposures:and
2	0885-3185:2006:Benaderette S:psychogenic:parkinsonism:a
2	0885-3185:2006:Ballanger B:paradoxical:kinesis:is
2	0885-3185:2006:Ardouin C:pathological:gambling:in
2	0885-3185:2005:Thobois S:can:chronic:subthalamic
2	0885-3185:2005:Simon N:end:of:dose
2	0885-3185:2005:Pinto S:changes:induced:by
2	0885-3185:2005:Kreisler A:corticobasal:degeneration:and
2	0885-3185:2005:Goetz C:evidence:based:medical
2	0885-3185:2005:Galanaud J:cigarette:smoking:and
2	0885-3185:2005:Elbaz A:risk:of:cancer
2	0885-3185:2005:Doe De Maindreville A:hallucinations:in:parkinson
2	0885-3185:2005:Chapuis S:impact:of:the
2	0885-3185:2005:Brefel Courbon C:effect:of:levodopa
2	0885-3185:2004:Zijlmans J:safety:of:entacapone
2	0885-3185:2004:Wenning G:development:and:validation
2	0885-3185:2004:Olanow C:levodopa:in:the
2	0885-3185:2004:Macia F:parkinson:s:disease
2	0885-3185:2004:Henderson J:partial:lesion:of
2	0885-3185:2003:Ziegler M:efficacy:of:piribedil
2	0885-3185:2003:Peran P:deficit:of:verb
2	0885-3185:2003:Le Cavorzin P:a:computer:model
2	0885-3185:2003:Jarraya B:parkinson:s:disease
2	0885-3185:2003:Funkiewiez A:acute:psychotropic:effects
2	0885-3185:2003:Elbaz A:s:y:polymorphism
2	0885-3185:2003:Courbon F:cardiac:mibg:scintigraphy
2	0885-3185:2003:Cochen V:transplantation:in:parkinson
2	0885-3185:2003:Brefel Courbon C:clinical:and:economic
2	0885-3185:2002:Tison F:application:of:the
2	0885-3185:2002:Smith L:repeated:administration:of
2	0885-3185:2002:Pollak P:intraoperative:micro:and
2	0885-3185:2002:Obinu M:neuroprotective:effect:of
2	0885-3185:2002:Muriel M:levodopa:but:not
2	0885-3185:2002:Durif F:long:term:follow
2	0885-3185:2002:Derkinderen P:micrographia:secondary:to
2	0885-3185:2002:Defebvre L:influence:of:pallidal
2	0885-3185:2002:Benazzouz A:intraoperative:microrecordings:of
2	0885-3185:2001:Rascol O:idazoxan:an:alpha
2	0885-3185:2001:Apartis E:fast:orthostatic:tremor
2	0885-3185:2001:Albanese A:consensus:statement:on
2	0885-3185:2000:Tison F:the:value:of
2	0885-3185:2000:Ghorayeb I:toward:a:primate
2	0885-3185:2000:Farrer M:linkage:exclusion:in
2	0885-3185:2000:Bejjani B:irregular:jerky:tremor
2	0885-3185:1999:Wenning G:progression:of:falls
2	0885-3185:1999:Vidailhet M:the:phenomenology:of
2	0885-3185:1999:Sibon I:parkinsonism:as:a
2	0885-3185:1999:Sabbagh N:cyp:d:polymorphism
2	0885-3185:1999:Rascol O:l:dopa:induced
2	0885-3185:1999:Durif F:worsening:of:levodopa
2	0885-3185:1998:Vidailhet M:pathology:of:symptomatic
2	0885-3185:1998:Rascol O:ropinirole:in:the
2	0885-3185:1998:Potagas C:clinical:assessment:of
2	0885-3185:1998:Krack P:treatment:of:tremor
2	0885-3185:1998:Krack P:inhibition:of:levodopa
2	0885-3185:1998:Hirsch E:iron:metabolism:and
2	0885-3185:1998:Fabre N:normal:frontal:perfusion
2	0885-3185:1998:Delalande I:do:visual:evoked
2	0885-3185:1998:Bejjani B:deep:brain:stimulation
2	0885-3185:1997:Tison F:dependency:in:parkinson
2	0885-3185:1997:Derex L:reversible:parkinsonism:hypophosphoremia
2	0885-3185:1997:Bonnet A:urinary:disturbances:in
2	0885-3185:1997:Andreu N:a:dose:ranging
2	0885-3185:1996:Tison F:effects:of:central
2	0885-3185:1996:Limousin P:abnormal:involuntary:movements
2	0885-3185:1996:Bordet R:sympathetic:skin:response
2	0885-3185:1995:Rascol O:abnormal:vestibuloocular:reflex
2	0885-3185:1995:Montastruc J:does:fluoxetine:aggravate
2	0885-3185:1995:Limousin P:bilateral:subthalamic:nucleus
2	0885-3185:1994:Tison F:glutathion:s:transferase
2	0885-3185:1994:Rascol O:naltrexone:an:opiate
2	0885-3185:1994:Marconi R:levodopa:induced:dyskinesias
2	0885-3185:1993:Broussolle E:relief:of:akinesia
2	0885-3185:1993:Allain H:symptomatic:effect:of
2	0885-3185:1989:Pourcher E:effects:of:etybenzatropine
2	0885-3185:1988:Viallet F:long:term:follow
2	0885-3185:1987:Montastruc J:levodopa:induced:regional
2	0885-3185:1987:Bonnet A:cerebrospinal:fluid:gaba
2	0767-3981:2012:Rascol O:a:proof:of
2	0767-3981:2010:Devos D:dopaminergic:and:non
2	0767-3981:1998:Montastruc J:fluoxetine:in:orthostatic
2	0767-3981:1993:Senard J:lack:of:yohimbine
2	0767-3981:1991:Milon D:cardiac:adrenoceptor:sensitivity
2	0767-3981:1990:Milon D:randomized:double:blind
2	0767-3981:1988:Allain H:randomized:double:blind
2	0767-0974:2007:Rasouri S:sirt:pgc:a
2	0765-1597:1987:Levy S:syndrome:de:wolff
2	0765-1597:1987:Delay M:apport:de:la
2	0753-3322:1999:Bonnet A:pathophysiology:of:parkinson
2	0753-3322:1999:Agid Y:parkinson:s:disease
2	0753-3322:1995:Muguet D:apomorphine:in:patients
2	0753-3322:1995:Allain H:explicit:and:procedural
2	0753-3322:1994:Delacourte A:pathological:tau:proteins
2	0733-2467:1993:Aranda B:effects:of:apomorphine
2	0584-8547:1978:Jarosz J:a:spectrometric:study
2	0369-8114:2014:Renner M:protein:aggregation:and
2	0369-8114:2007:Lesage S:lrrk:a:link
2	0364-5134:2013:Engeln M:levodopa:gains:psychostimulant
2	0364-5134:2012:Tass P:coordinated:reset:has
2	0364-5134:2012:Hagberg H:inflammation:during:fetal
2	0364-5134:2012:Freundt E:neuron:to:neuron
2	0364-5134:2011:Piallat B:subthalamic:neuronal:firing
2	0364-5134:2011:Elbaz A:independent:and:joint
2	0364-5134:2011:Corvol J:the:comt:val
2	0364-5134:2010:Stocchi F:initiating:levodopa:carbidopa
2	0364-5134:2010:Rylander D:maladaptive:plasticity:of
2	0364-5134:2010:Godefroy O:dysexecutive:syndrome:diagnostic
2	0364-5134:2010:Arnulf I:sleep:induced:by
2	0364-5134:2009:Elbaz A:professional:exposure:to
2	0364-5134:2009:Ballanger B:stimulation:of:the
2	0364-5134:2008:Ross O:genomic:investigation:of
2	0364-5134:2008:Goetz C:parkinson:s:disease
2	0364-5134:2006:Mcdonnell S:complex:segregation:analysis
2	0364-5134:2005:Lesage S:g:s:lrrk
2	0364-5134:2004:Elbaz A:cyp:d:polymorphism
2	0364-5134:2003:Whone A:slower:progression:of
2	0364-5134:2003:Rascol O:limitations:of:current
2	0364-5134:2003:Lohmann E:how:much:phenotypic
2	0364-5134:2003:Hunot S:neuroinflammatory:processes:in
2	0364-5134:2002:Valente E:park:linked:parkinsonism
2	0364-5134:2002:Escola L:disruption:of:the
2	0364-5134:2000:Hirsch E:nigrostriatal:system:plasticity
2	0364-5134:2000:Benabid A:dyskinesias:and:the
2	0364-5134:1999:Rascol O:abt:a:d
2	0364-5134:1999:Brown R:impact:of:deep
2	0364-5134:1999:Ardouin C:bilateral:subthalamic:or
2	0364-5134:1998:Vaughan J:the:synuclein:ala
2	0364-5134:1998:Murer M:chronic:levodopa:is
2	0364-5134:1998:Krack P:opposite:motor:effects
2	0364-5134:1998:Hirsch E:glial:cells:and
2	0364-5134:1995:Remy P:clinical:correlates:of
2	0364-5134:1995:Anglade P:plasticity:of:nerve
2	0364-5134:1994:Vidailhet M:eye:movements:in
2	0364-5134:1994:Vermersch A:sequences:of:memory
2	0364-5134:1994:Kastner A:decreased:tyrosine:hydroxylase
2	0364-5134:1993:Vermersch P:dementia:in:parkinson
2	0364-5134:1991:Gaspar P:alterations:of:dopaminergic
2	0364-5134:1990:Hirsch E:does:adrenal:graft
2	0364-5134:1990:Dubois B:cholinergic:deficiency:and
2	0364-5134:1989:Scherman D:striatal:dopamine:deficiency
2	0364-3190:1990:Deloncle R:mechanism:of:alzheimer
2	0362-5664:1997:Courty E:psychiatric:and:sexual
2	0362-5664:1996:Rascol O:ropinirole:in:the
2	0362-5664:1996:Llau M:a:study:of
2	0362-5664:1996:Bordet R:lack:of:relation
2	0362-5664:1995:Limousin P:acute:administration:of
2	0362-5664:1994:Tison F:apomorphine:increases:blood
2	0362-5664:1994:Bordet R:genetic:polymorphism:of
2	0362-5664:1994:Bagheri H:lacrimation:in:parkinson
2	0362-5664:1993:Senard J:effects:of:yohimbine
2	0362-5664:1993:Gervason C:reproducibility:of:motor
2	0362-5664:1993:Durif F:relation:between:clinical
2	0362-5664:1992:Feve A:chronic:administration:of

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/corpus/ParkinsonFrance.storage/ParkinsonFranceV1/Data/Main/Merge/Idat.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration) - Merge (Accueil) Index « Idat.i » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration) - Merge (Accueil)Index « Idat.i » - tête de navigation

Index : Idat.i

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

La maladie de Parkinson en France (serveur d'exploration) - Merge (Accueil)

Index « Idat.i » - tête de navigation